The opening comes at a pivotal moment for Canada’s biotechnology and life sciences sector. Over the past year, the sector has moved into the centre of several major federal priorities, from investment and tax competitiveness to health security, AI, and defence-related innovation. Recent measures, including reforms to the Scientific Research and Experimental Development (SR&ED) tax incentive, the new Venture and Growth Capital Catalyst Initiative, Health Emergency Readiness Canada, and the recognition of life sciences in Canada’s Defence Industrial Strategy and national AI strategy, reflect the growing recognition of biotechnology as a strategic national asset and an important driver of Canada’s long-term competitiveness.